Skip to main content
Fig. 2 | BMC Research Notes

Fig. 2

From: Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells

Fig. 2

Dose response curves for cisplatin a, gefitinib b, gemcitabine c and vinorelbine d combined with bortezomib in the least (left panel) and most (right panel) resistant cell line, in the cell line panel used in this study, in regard to the therapeutic drug. The effect is defined as 1 minus the fraction of living cells in a drug-treated sample compared with an untreated sample

Back to article page